biostudies-literatureCha HHKorea Health Industry Development InstituteMinistry of Health and Welfare455-459https://www.ebi.ac.uk/biostudies/studies/S-EPMC8925962biostudies-literatureUnknown37(2)<h4>Background/aims</h4>Data comparing the antibody responses of different coronavirus disease 2019 (COVID-19) vaccine platforms according to dose with natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection-induced antibody responses are limited.<h4>Methods</h4>Blood samples from adult patients with mild and severe COVID-19 and healthcare workers who received ChAdOx1 nCoV-19 vaccine (2nd dose at 12-week intervals) and BNT162b2 vaccine (2nd dose at 3-week intervals) were collected and compared by immunoglobulin G immune responses to SARS-CoV-2 specific spike protein using an in-house-developed enzyme-linked immunosorbent assay.<h4>Results</h4>A total of 53 patients, including 12 and 41 with mild and severe COVID-19, respectively, were analyzed. In addition, a total oThe Korean journal of internal medicineComparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19.PMC8925962HW20C2062Kim SHJung JKim JYBae SLim SYKwon JSCha HHfalseComparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19.<h4>Background/aims</h4>Data comparing the antibody responses of different coronavirus disease 2019 (COVID-19) vaccine platforms according to dose with natural severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection-induced antibody responses are limited.<h4>Methods</h4>Blood samples from adult patients with mild and severe COVID-19 and healthcare workers who received ChAdOx1 nCoV-19 vaccine (2nd dose at 12-week intervals) and BNT162b2 vaccine (2nd dose at 3-week intervals) were collected and compared by immunoglobulin G immune responses to SARS-CoV-2 specific spike protein using an in-house-developed enzyme-linked immunosorbent assay.<h4>Results</h4>A total of 53 patients, including 12 and 41 with mild and severe COVID-19, respectively, were analyzed. In addition, a total o2022-01-01T00:00:00Z2022 Mar2025-04-04T07:44:09.737Z2025-04-04T07:44:09.737ZS-EPMC89259623527244410.3904/kjim.2021.409